Jove
Visualize
Contact Us

Related Experiment Videos

[ED-71].

Koichi Endo1, Naoki Tsuji

  • 1Chugai Pharmaceutical Co., Ltd.

Clinical Calcium
|March 19, 2005
PubMed
Summary
This summary is machine-generated.

ED-71, a vitamin D analog, effectively increases bone mineral density in osteoporotic patients without causing hypercalcemia. This promising osteoporosis treatment shows a strong effect on bone formation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term expandable auricular chondrocytes reveal a conserved nine-gene decline module underlying senescence-independent dedifferentiation.

Regenerative therapy·2026
Same author

Participation in Community Gathering Places and Subsequent Care Costs in Older Adults: A 2-Year Follow-Up Study.

Journal of the American Medical Directors Association·2026
Same author

Gefitinib-Induced Heart Failure Confirmed by a Rechallenge in a Patient with EGFR-Mutated Lung Adenocarcinoma.

Internal medicine (Tokyo, Japan)·2026
Same author

Role of WIF-1 in regulating chondrocyte dedifferentiation and matrix production through WNT pathway.

Regenerative therapy·2026
Same author

Chemical exchange saturation transfer imaging and diffusion weighted imaging for colon 26 tumor bearing mice.

Scientific reports·2025
Same author

Inhibition of cysteine protease disturbs the topological relationship between bone resorption and formation in vitro.

Journal of bone and mineral metabolism·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Context:

  • Osteoporosis is a significant health concern characterized by reduced bone mass and increased fracture risk.
  • Current treatments for osteoporosis have limitations, necessitating the development of novel therapeutic agents.
  • Vitamin D analogs are being investigated for their potential to manage bone metabolism and treat osteoporosis.

Purpose:

  • To evaluate the efficacy and safety of ED-71, a novel vitamin D analog, in increasing bone mineral density (BMD) and improving bone metabolism.
  • To assess the effect of ED-71 on bone formation and resorption markers in patients with osteoporosis.
  • To determine the dose-dependent effects of ED-71 on BMD and bone turnover markers.

Summary:

  • ED-71, a potent analog of 1,25(OH)2D3, demonstrated dose-dependent increases in lumbar spine BMD in ovariectomized rats without inducing hypercalcemia.

Related Experiment Videos

  • In osteoporotic patients, daily oral administration of ED-71 for six months significantly increased BMD at L(2-4) in a dose-dependent manner.
  • ED-71 suppressed urinary deoxypyridinoline, a bone resorption marker, without significantly affecting serum osteocalcin, a bone formation marker, suggesting a preferential effect on bone formation.

    • Impact:

    • ED-71 shows potential as a safe and effective therapeutic agent for osteoporosis, particularly for increasing bone mass and strength.
    • The findings suggest ED-71 may offer a therapeutic advantage by promoting bone formation with a reduced risk of hypercalcemia.
    • ED-71 represents a promising candidate for future clinical development in the management of osteoporosis.